Diltiazem

證據等級: L5

預測適應症: 1 個

Diltiazem: Repurposing Evaluation — Insufficient Data to Complete Assessment

One-Sentence Summary

Diltiazem (DrugBank: DB00343) is a cardiovascular calcium channel blocker with established clinical use globally. This Evidence Pack contains no TxGNN predicted indications, making a standard drug repurposing evaluation impossible at this stage. Two data gaps of Blocking / High severity must be resolved before the evaluation can proceed.

Quick Overview

Item	Content
Original Indication	Not available in this Evidence Pack
Predicted New Indication	No prediction generated
TxGNN Prediction Score	—
Evidence Level	Not evaluable (prediction not yet generated)
Taiwan Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why This Evaluation Cannot Proceed

This Evidence Pack is missing three critical elements that are prerequisites for a drug repurposing evaluation:

1. No TxGNN predictions (predicted_indications is empty) The core output of the repurposing pipeline — the disease prediction list — is absent from this pack. Without a predicted indication target, there is no basis for clinical, mechanistic, or evidence review. This is the most fundamental gap.

2. Mechanism of action (MOA) unavailable The DrugBank query returned a record (query log ID 3, status: success), but MOA data was not populated in the pack. Mechanistic plausibility analysis — the primary justification for repurposing — cannot be performed without this.

3. Original indication data not extracted The original_indications field is empty. While the TFDA package insert query returned a result (query log ID 4, status: success), its contents were not parsed into the pack. Baseline disease characterization is therefore incomplete.

Until these gaps are resolved, the following report sections cannot be generated:

Clinical Trial Evidence
Literature Evidence
Mechanism Rationale
Cytotoxicity Assessment

Taiwan Market Information

Diltiazem has 0 approved authorizations in the TFDA database and is classified as not marketed in Taiwan. No product listing is available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Diltiazem (DB00343) is structurally incomplete — the TxGNN prediction output is absent and two upstream data gaps (Blocking + High severity) have not been remediated. No repurposing evaluation can be generated under these conditions.

To proceed, the following is needed:

[Blocking] Run TxGNN prediction pipeline for Diltiazem to generate predicted_indications — this is the prerequisite for the entire evaluation
[Blocking] Parse the TFDA package insert PDF already retrieved (query log ID 4) to populate original_indications, key_warnings, and contraindications
[High] Query DrugBank API (DB00343) to retrieve MOA, drug categories, and toxicity data
[Medium] Re-run evidence collection (ClinicalTrials.gov + PubMed) for the predicted indication once TxGNN output is available
[Low] Confirm whether DDI data should be sourced from an alternative database, as the current DDI query returned not_found
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.